Evidence map›Paper›PMID 25313193›Full record

SynthesisNeuro-oncology2015

The worldwide incidence and prevalence of primary brain tumors: a systematic review and meta-analysis.

Paula de Robles, Kirsten M Fiest, Alexandra D Frolkis, Tamara Pringsheim, Callie Atta, Christine St Germaine-Smith, Lundy Day, Darren Lam, Nathalie Jette

2 registry-linked trialsAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Neuro-oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 144 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
144citing papers in PubMed, 11 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04773093 phase1 / phase2unknown statusnot on this mapstarted 2021, after this paper: background citation

Continous Intravenous Lidocaine Infusion Intraoperative for Craniotomy Tumor Removal Surgery: Effect to Brain Relaxation, Opioid Consumption and Postoperative Cognitive Status

TypeinterventionalSponsorIndonesia UniversityRan2021 to 2021Enrolled50ConditionsCraniotomy Tumor Removal SurgeryArmsContinous Intravenous Lidocaine Infusion, Placebo
NCT06249113 nacompletednot on this mapstarted 2023, after this paper: background citation

Effectiveness of Adjuvant Continuous Lidocaine in General Anesthesia on Depth of Anesthesia (qCON), Pain Response (qNOX), and Blood Sugar Levels in Elective Primary Tumor Craniotomy Surgery

TypeinterventionalSponsorIndonesia UniversityRan2023 to 2024Enrolled60ConditionsSurgery, Anesthesia, Functional, Haemodynamic InstabilityArmsNaCl 0.9%, Adjuvant lidocaine continous
3 · Its place in the literature

Who cites it

144 citing papers in PubMed, 11 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Interventions to reduce the time to diagnosis of brain tumours.The Cochrane database of systematic reviews · 2020
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Review
  13. Rehabilitation in patients with primary brain tumors: a scoping review of current guideline recommendations.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

84 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Paula de RoblesDepartment of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada (P.d.R., K.M.F., C.A., T.P., C.S., L.D., D.L., N.J.); Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada (P.d.R., K.F., T.P., D.L., N.J.); Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada (K.F., A.D.F., T.P., N.J.); Institute for Public Health, University of Calgary, Calgary, Alberta, Canada (K.F, A.D.F., T.P., N.J.); Department of Oncology, University of Calgary, Calgary, Alberta, Canada (P.d.R.).
Kirsten M FiestDepartment of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada (P.d.R., K.M.F., C.A., T.P., C.S., L.D., D.L., N.J.); Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada (P.d.R., K.F., T.P., D.L., N.J.); Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada (K.F., A.D.F., T.P., N.J.); Institute for Public Health, University of Calgary, Calgary, Alberta, Canada (K.F, A.D.F., T.P., N.J.); Department of Oncology, University of Calgary, Calgary, Alberta, Canada (P.d.R.).
Alexandra D FrolkisDepartment of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada (P.d.R., K.M.F., C.A., T.P., C.S., L.D., D.L., N.J.); Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada (P.d.R., K.F., T.P., D.L., N.J.); Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada (K.F., A.D.F., T.P., N.J.); Institute for Public Health, University of Calgary, Calgary, Alberta, Canada (K.F, A.D.F., T.P., N.J.); Department of Oncology, University of Calgary, Calgary, Alberta, Canada (P.d.R.).
Tamara PringsheimDepartment of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada (P.d.R., K.M.F., C.A., T.P., C.S., L.D., D.L., N.J.); Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada (P.d.R., K.F., T.P., D.L., N.J.); Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada (K.F., A.D.F., T.P., N.J.); Institute for Public Health, University of Calgary, Calgary, Alberta, Canada (K.F, A.D.F., T.P., N.J.); Department of Oncology, University of Calgary, Calgary, Alberta, Canada (P.d.R.).
Callie AttaDepartment of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada (P.d.R., K.M.F., C.A., T.P., C.S., L.D., D.L., N.J.); Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada (P.d.R., K.F., T.P., D.L., N.J.); Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada (K.F., A.D.F., T.P., N.J.); Institute for Public Health, University of Calgary, Calgary, Alberta, Canada (K.F, A.D.F., T.P., N.J.); Department of Oncology, University of Calgary, Calgary, Alberta, Canada (P.d.R.).
Christine St Germaine-SmithDepartment of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada (P.d.R., K.M.F., C.A., T.P., C.S., L.D., D.L., N.J.); Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada (P.d.R., K.F., T.P., D.L., N.J.); Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada (K.F., A.D.F., T.P., N.J.); Institute for Public Health, University of Calgary, Calgary, Alberta, Canada (K.F, A.D.F., T.P., N.J.); Department of Oncology, University of Calgary, Calgary, Alberta, Canada (P.d.R.).
Lundy DayDepartment of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada (P.d.R., K.M.F., C.A., T.P., C.S., L.D., D.L., N.J.); Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada (P.d.R., K.F., T.P., D.L., N.J.); Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada (K.F., A.D.F., T.P., N.J.); Institute for Public Health, University of Calgary, Calgary, Alberta, Canada (K.F, A.D.F., T.P., N.J.); Department of Oncology, University of Calgary, Calgary, Alberta, Canada (P.d.R.).
Darren LamDepartment of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada (P.d.R., K.M.F., C.A., T.P., C.S., L.D., D.L., N.J.); Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada (P.d.R., K.F., T.P., D.L., N.J.); Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada (K.F., A.D.F., T.P., N.J.); Institute for Public Health, University of Calgary, Calgary, Alberta, Canada (K.F, A.D.F., T.P., N.J.); Department of Oncology, University of Calgary, Calgary, Alberta, Canada (P.d.R.).
Nathalie JetteDepartment of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada (P.d.R., K.M.F., C.A., T.P., C.S., L.D., D.L., N.J.); Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada (P.d.R., K.F., T.P., D.L., N.J.); Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada (K.F., A.D.F., T.P., N.J.); Institute for Public Health, University of Calgary, Calgary, Alberta, Canada (K.F, A.D.F., T.P., N.J.); Department of Oncology, University of Calgary, Calgary, Alberta, Canada (P.d.R.).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrimary brain tumors are a heterogeneous group of benign and malignant tumors arising from the brain parenchyma and its surrounding structures. The epidemiology of these tumors is poorly understood. The aim of our study is to systematically review the latest literature on the incidence and prevalence of primary brain tumors.

methodsThe systematic review and meta-analysis were conducted according to a predetermined protocol and established guidelines. Only studies reporting on data from 1985 onward were included. Articles were included if they met the following criteria: (i) original research, (ii) population based, (iii) reported an incidence or prevalence estimate of primary brain tumors.

resultsFrom the 53 eligible studies overall, 38 were included in the meta-analysis. A random-effects model found the overall incidence rate of all brain tumors to be 10.82 (95% CI: 8.63-13.56) per 100 000 person-years. The incidence proportion estimates were heterogeneous, even among the same tumor subtypes, and ranged from 0.051 per 100 000 (germ cell tumors) to 25.48 per 100 000 (all brain tumors). There were insufficient data to conduct a meta-analysis of the prevalence of primary brain tumors.

conclusionsThere is a need for more accurate and comparable incidence and prevalence estimates of primary brain tumors across the world. A standardized approach to the study of the epidemiology of these tumors is needed to better understand the burden of brain tumors and the possible geographical variations in their incidence.

Indexed as

Age FactorsBrain NeoplasmsCross-Sectional StudiesFemaleHumansIncidenceMalePrevalenceSex Factorsbrain tumorincidencemeta-analysisprevalencesystematic review

Identifiers

PMID25313193
PMCPMC4483114

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.